临床试验专区:重塑根治性

IF 1.1 Q4 ONCOLOGY Kidney Cancer Pub Date : 2021-11-15 DOI:10.3233/kca-210002

M. Parikh

{"title":"临床试验专区:重塑根治性","authors":"M. Parikh","doi":"10.3233/kca-210002","DOIUrl":null,"url":null,"abstract":"The Clinical Trials Corner of Kidney Cancer highlights planned or ongoing high-impact studies in renal cell carcinoma (RCC). In this issue, we revisit the RADICAL trial, an important study evaluating the potential beneﬁ t of Radium-223 therapy in RCC patients with bone metastases, which has recently been amended. In the future, attention to a speciﬁ c trial, us metastases turnover in metastatic castration An Phase I trial of Radium-223 combined in","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Trials Corner: Reimagining RADICAL\",\"authors\":\"M. Parikh\",\"doi\":\"10.3233/kca-210002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Clinical Trials Corner of Kidney Cancer highlights planned or ongoing high-impact studies in renal cell carcinoma (RCC). In this issue, we revisit the RADICAL trial, an important study evaluating the potential beneﬁ t of Radium-223 therapy in RCC patients with bone metastases, which has recently been amended. In the future, attention to a speciﬁ c trial, us metastases turnover in metastatic castration An Phase I trial of Radium-223 combined in\",\"PeriodicalId\":17823,\"journal\":{\"name\":\"Kidney Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2021-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/kca-210002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/kca-210002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症临床试验角强调了肾细胞癌（RCC）的计划或正在进行的高影响研究。在本期中，我们回顾了RADICAL试验，这是一项重要的研究，评估了镭-223治疗骨转移RCC患者的潜在益处，该试验最近进行了修订。未来，我们将关注一项特殊的试验，即转移性阉割中的转移转移转移率

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Clinical Trials Corner: Reimagining RADICAL

The Clinical Trials Corner of Kidney Cancer highlights planned or ongoing high-impact studies in renal cell carcinoma (RCC). In this issue, we revisit the RADICAL trial, an important study evaluating the potential beneﬁ t of Radium-223 therapy in RCC patients with bone metastases, which has recently been amended. In the future, attention to a speciﬁ c trial, us metastases turnover in metastatic castration An Phase I trial of Radium-223 combined in

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Kidney Cancer Multiple-

CiteScore

0.90

自引率

8.30%

发文量